Results 11 to 20 of about 6,415 (210)
EUCAST technical note on anidulafungin [PDF]
Clinical Microbiology and Infection, 2011 The European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing has determined breakpoints for anidulafungin for Candida spp. This Technical Note is based on the EUCAST anidulafungin rationale document (available at: http://www.eucast.org). Species-specific breakpoints for C.
Cornelia Lass-Flörl +2 more
exaly +5 more sources
Anidulafungin-Induced Suicidal Erythrocyte Death
Cellular Physiology and Biochemistry, 2016 Background/Aims: The novel antifungal drug Anidulafungin is used for the treatment of diverse fungal infections including candidiasis and aspergillosis.
Thomas Peter +3 more
doaj +2 more sources
Anidulafungin induced reversible thrombocytopenia in a patient: A case report
Medicine Science, 2018 Anidulafungin is a semisynthetic antifungal agent which is an echinocandin. Here, we presented elderly patient developed reversible severe thrombocytopenia due to anidulafungin.
Zubeyir Cebeci +3 more
doaj +2 more sources
Brazilian Journal of Pharmaceutical Sciences, 2019 Candida glabrata has emerged as a common cause of serious life-threatening fungal infections, largely owing to their low susceptibility to azole antifungals. Recent guidance indicates the use of echinocandins as the first-choice drug for the treatment of
Camila Hatwig +5 more
doaj +2 more sources
Anidulafungin in the treatment of invasive fungal infections
Therapeutics and Clinical Risk Management, 2008 Kathryn Sabol, Tawanda GumboUniversity of Texas Southwestern Medical Center, Dallas, TX, USAAbstract: More antifungal agents have reached clinical use in the past two decades than at any other time.
Kathryn Sabol, Tawanda Gumbo
doaj +1 more source
Anidulafungin for the treatment of invasive candidiasis [PDF]
Clinical Microbiology and Infection, 2011 Candidaemia/invasive candidiasis (C/IC) is the most frequently occurring invasive fungal infection worldwide, with a particularly strong impact and high incidence in the intensive-care unit, where there is a need for new treatment options and strategies. The echinocandin anidulafungin has broad in vitro activity against a wide range of Candida species,
Mayr, A., Aigner, M., Lass-Flörl, C.
openaire +3 more sources
Anidulafungin, a New Echinocandin
Drugs, 2009 Anidulafungin is a new echinocandin with potent in vitro activity against Aspergillus and Candida species, including those resistant to fluconazole and amphotericin B. Results of several clinical trials indicate that anidulafungin is effective in treating oesophageal candidiasis, including azole-refractory disease.
G. Morace +3 more
core +8 more sources
Pharmacokinetics of anidulafungin in critically ill patients with Candida peritonitis [PDF]
International Journal of Infectious Diseases, 2019 Objective: To describe the pharmacokinetic (PK) profile of anidulafungin and to evaluate its concentration in the peritoneal fluid (PF) of patients suspected of suffering from peritoneal infection undergoing abdominal surgery, in order to ensure that ...
D.V. Pérez Civantos +5 more
doaj +2 more sources
Discovery of Small-Molecule PD-L1 Inhibitors via Virtual Screening and Their Immune-Mediated Anti-Tumor Effects [PDF]
PharmaceuticalsBackground/Objectives: Monoclonal antibodies targeting the PD-1/PD-L1 immune checkpoint have achieved clinical success but face drawbacks such as poor oral bioavailability, limited tumor penetration, and immune-related adverse events.
Chunlai Feng +6 more
doaj +2 more sources
Fast detection of synergy and antagonism in antifungal combinations used against Candida albicans clinical isolates [PDF]
Scientific ReportsThe rise in antifungal resistance has limited treatment options for serious fungal infections, emphasizing the need for effective combination therapies. However, low-cost and rapid systems to evaluate synergy and antagonism in antifungal combinations are
Hanna Lundvik +5 more
doaj +2 more sources